A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations By Ogkologos - May 12, 2026 275 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BIOMEDE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib December 1, 2022 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Woman Showed Up To Their Wedding And Stole All Their Gifts.... March 11, 2019 Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... May 18, 2021 Load more HOT NEWS Addressing the Barriers to Minority Participation in Cancer Clinical Trials Coping With the Holidays During COVID-19 and Cancer How My Cancer Diagnosis Has Fueled My Work in Improving Access... Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated...
